Profil
Gerhard Wolff worked as the Director of Preclinical & Clinical Development at Revotar Biopharmaceuticals AG from 2009 to 2012.
Prior to that, he worked as a Principal at Cornell University and the National Institute of Health Policy.
Wolff earned a doctorate degree from Universität Leipzig in 1992.
Ehemalige bekannte Positionen von Gerhard Wolff
| Unternehmen | Position | Ende |
|---|---|---|
| National Institute of Health Policy | Corporate Officer/Principal | - |
Cornell University
 Cornell University Other Consumer ServicesConsumer Services Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY. | Corporate Officer/Principal | - |
Revotar Biopharmaceuticals AG
 Revotar Biopharmaceuticals AG Pharmaceuticals: MajorHealth Technology Revotar Biopharmaceuticals AG specializes in the research and development of anti-inflammatory drugs. The firm develops drugs for the therapy and treatment of inflammatory disorders such as psoriasis, asthma and acute lung injuries, and chronic obstructive pulmonary diseases. Its focus areas include product licensing, drug discovery, and clinical development. The firm also engages in partnerships and projects with biotechnology research institutions and pharmaceutical enterprises. The company was founded in August 2000 and is headquartered in Hennigsdorf, Germany. | Corporate Officer/Principal | - |
Ausbildung von Gerhard Wolff
| Universität Leipzig | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Revotar Biopharmaceuticals AG
Revotar Biopharmaceuticals AG Pharmaceuticals: MajorHealth Technology Revotar Biopharmaceuticals AG specializes in the research and development of anti-inflammatory drugs. The firm develops drugs for the therapy and treatment of inflammatory disorders such as psoriasis, asthma and acute lung injuries, and chronic obstructive pulmonary diseases. Its focus areas include product licensing, drug discovery, and clinical development. The firm also engages in partnerships and projects with biotechnology research institutions and pharmaceutical enterprises. The company was founded in August 2000 and is headquartered in Hennigsdorf, Germany. | Health Technology |
| National Institute of Health Policy |
